Japan CRISPR Market (2025-2030)
The Japan CRISPR Market was valued at $127.7 Million in 2025 and projected to reach to $228.2 Million by 2030, representing a compound annual growth rate of 12.3%. Japan's CRISPR market is poised for sustained growth through 2030, driven by increasing prevalence of genetic disorders, rising healthcare expenditure, and growing clinical adoption of gene-editing therapies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Japan CRISPR Market Trends and Insights
- Japan's advanced healthcare infrastructure, strong investment in biotechnology research, and supportive regulatory environment position the country as a key player in the Asia Pacific CRISPR landscape.
- The market expansion reflects Japan's commitment to precision medicine and gene-editing therapeutics. Japan's CRISPR sector benefits from significant government funding, collaboration between academic institutions and pharmaceutical companies, and a growing patient population seeking innovative treatments.
- Japan's aging demographic and prevalence of genetic disorders drive demand for CRISPR-based solutions.
- Between 2025 and 2030, Japan is expected to see increased clinical trials, regulatory approvals, and commercialization of CRISPR therapies, solidifying its position as a regional innovation hub. Japan's market growth outpaces the global average, reflecting the country's technological expertise and healthcare spending capacity.
- Strategic partnerships and investments by Japanese biotech firms in CRISPR development underscore Japan's determination to lead in next-generation therapeutics..
Key Market Statistics
- CAGR (2025-2030) 12.3% CAGR
- Market Size, 2025 ~USD 127.7 Million
- Forecast, 2030 ~USD 228.2 Million
- Country Japan
Japan CRISPR Market Overview
Market Valuation Growth :
Japan's CRISPR market is valued at $127.7 million in 2025 and is projected to reach $228.2 million by 2030, demonstrating strong market expansion driven by increasing adoption of gene-editing technologies in therapeutic applications.
Advanced Healthcare Infrastructure :
Japan's world-class healthcare system and cutting-edge medical facilities provide an ideal environment for CRISPR technology development, clinical trials, and commercialization of gene-editing therapies.
Robust Biotech Investment :
Japan's government and private sector continue to invest heavily in biotechnology research and development, with significant funding directed toward CRISPR-based therapeutics and precision medicine initiatives.
Supportive Regulatory Framework :
Japan's regulatory authorities have established clear pathways for CRISPR drug approval and commercialization, fostering innovation while maintaining rigorous safety and efficacy standards for gene-editing treatments.
Japan CRISPR Market Dynamics
- The country's strong intellectual property protections and collaborative research ecosystem between academic institutions and pharmaceutical companies accelerate innovation cycles.
- Japan's aging population and focus on precision medicine create significant demand for CRISPR-based treatments targeting hereditary diseases and cancers.
- Strategic partnerships between Japanese biotech firms and global leaders will further expand market opportunities and therapeutic applications..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- Japan's CRISPR market is valued at $127.7 million in 2025 and is forecast to reach $228.2 million by 2030, growing at a 12.3% CAGR.
- Japan's growth rate exceeds the global CRISPR market CAGR, driven by advanced healthcare infrastructure and biotech investment.
- Japan's aging population and genetic disorder prevalence create strong demand for CRISPR-based therapeutic solutions.
- Japan's regulatory support and academic-industry collaboration position the country as a leading CRISPR innovation hub in Asia Pacific.
CRISPR Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | GRNA SYNTHESIS & CELL LINE DEVELOPMENT (Service) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 11.2% from 2025 to 2030 |
| Largest Segment | PRODUCT (Offering) |
| Market Size Base Year (Billions) | ~USD 3.22 (2025) |
| Revenue Forecast (Billions) | ~USD 5.47 (2030) |
| Segments Covered | Offering, Type, End User, Service, Application, Product |
Japan CRISPR Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Product
- Products
- Service
- Services
By Type
- Crispr Kits & Enzymes
- Crispr Libraries
- Other Products
By End User
- Academic & Research Institutes
- Other End Users
- Pharmaceutical & Biotechnological Companies
- Pharmaceutical & Biotechnology Companies
By Service
- Grna Synthesis & Cell Line Development
- Other Services
- Screening & Validation
By Application
- Agriculture
- Drug Discovery & Development
- Other Applications
By Product
- Crispr Kits & Enzymes
- Crispr Libraries
- Other Products
JAPAN: CRISPR SERVICES MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 12.5 | 13.7 | 15.4 | 17.5 | 19.7 | 22.3 | 25.3 | 28.7 | 13.2 |
| OTHER END USERS | 13.7 | 15 | 16.7 | 18.7 | 20.8 | 23.3 | 26.1 | 29.2 | 11.8 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 16.8 | 18.3 | 20.6 | 23.4 | 26.5 | 30 | 34.1 | 38.7 | 13.4 |
| TOTAL | 43.1 | 46.9 | 52.7 | 59.5 | 67.1 | 75.7 | 85.5 | 96.5 | 12.9 |
JAPAN: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 28.5 | 30.2 | 33.8 | 38 | 42.6 | 47.7 | 53.6 | 60.2 | 12.2 |
| OTHER END USERS | 38.3 | 40.8 | 45.5 | 51 | 57.1 | 63.9 | 71.7 | 80.4 | 12.1 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 40.6 | 43.1 | 48.4 | 54.5 | 61.3 | 69 | 77.8 | 87.6 | 12.6 |
| TOTAL | 107.4 | 114.1 | 127.7 | 143.5 | 160.9 | 180.6 | 203.1 | 228.2 | 12.3 |
Target Audience
- Pharmaceutical & Biotech Companies : Develop market entry strategies, assess competitive positioning, and identify licensing or acquisition opportunities in Japan's growing CRISPR therapeutics sector with detailed market sizing and growth forecasts.
- Healthcare Investors & Venture Capitalists : Evaluate investment potential in Japanese CRISPR startups and established biotech firms with comprehensive market data, growth projections, and analysis of regulatory and commercial success factors.
- Medical Device & Diagnostic Companies : Understand Japan's CRISPR market dynamics to identify complementary product opportunities, partnership potential, and market expansion strategies within the precision medicine and gene-editing landscape.
- Government & Policy Makers : Inform healthcare policy, research funding allocation, and regulatory framework development with evidence-based market intelligence on Japan's CRISPR sector growth and innovation trends.
- Academic & Research Institutions : Benchmark Japan's CRISPR research capabilities, identify collaboration opportunities with industry partners, and understand commercialization pathways for academic discoveries in gene-editing technologies.
Reasons to Buy this Report
- Market Size & Growth Projections : Access detailed valuation data showing Japan's CRISPR market growing from $127.7M to $228.2M (2030) at 12.3% CAGR, enabling accurate revenue forecasting and investment planning specific to the Japanese market.
- Competitive Landscape Analysis : Identify key Japanese and international CRISPR players operating in Japan, their market positioning, product pipelines, and strategic initiatives to inform competitive strategy and partnership opportunities.
- Regulatory & Reimbursement Insights : Understand Japan's unique regulatory approval pathways, reimbursement policies, and healthcare system dynamics that directly impact CRISPR product commercialization timelines and market penetration rates.
- Clinical Application Opportunities : Discover high-priority therapeutic areas and disease indications where CRISPR adoption is accelerating in Japan, including genetic disorders, oncology, and rare diseases with significant unmet medical needs.
- Investment & Partnership Strategy : Leverage Japan-specific market intelligence to identify funding opportunities, R&D collaboration prospects, and strategic acquisition targets within Japan's thriving biotech and pharmaceutical ecosystem.
Frequently asked questions
What is the current size of Japan's CRISPR market in 2025?
Japan's CRISPR market is valued at $127.7 million in 2025, reflecting strong investment in gene-editing technologies and precision medicine.
What is the projected size of Japan's CRISPR market by 2030?
Japan's CRISPR market is projected to reach $228.2 million by 2030, representing significant expansion over the five-year forecast period.
What is the CAGR for Japan's CRISPR market?
Japan's CRISPR market is expected to grow at a compound annual growth rate of 12.3% from 2025 to 2030.
What factors are driving growth in Japan's CRISPR market?
Japan's CRISPR market growth is driven by advanced healthcare infrastructure, government funding, academic-industry partnerships, an aging population, and increasing prevalence of genetic disorders.
How does Japan's CRISPR market compare to global trends?
Japan's CRISPR market CAGR of 12.3% exceeds the global average of 11.2%, demonstrating Japan's strong position and accelerated adoption of CRISPR technologies.
RESEARCH METHODOLOGY
The research study utilized a range of secondary sources, directories, and databases to gather important information for analyzing the global CRISPR market. In addition, extensive interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level executives from leading market players, and industry consultants. These interviews helped obtain and verify qualitative and quantitative information, allowing for a comprehensive evaluation of the market's growth scenarios. The global market size was estimated through secondary research, using both top-down and bottom-up approaches, followed by data triangulation that incorporated insights from industry experts to determine the final market size.
Secondary Research
Secondary research was primarily utilized to identify and gather information for the technical, market-oriented, and commercial analysis of the CRISPR market. The sources consulted for this study included the Broad Institute, Innovative Genomics Institute (IGI), National Institute of Food and Agriculture, International Chromosome and Genome Society (ICGS), National Human Genome Research Institute (NHGRI), Asia Pacific Society of Human Genetics (APSHG), Genetics Society of America (GSA), European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Center for Cellular and Molecular Biology (CCMB) in India, and the Department of Biotechnology (DBT) in India.
Additional secondary sources comprised academic journals, company websites, corporate and regulatory filings such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and various trade, business, and professional associations. These sources were also instrumental in gathering essential information about key market players, market segmentation related to industry trends, developments at the regional and country levels, and technology prospects.
The secondary data collected was analyzed to determine the global CRISPR market size, which was subsequently validated through primary research.
Primary Research
Extensive primary research was conducted after gathering foundational knowledge about the global CRISPR market through secondary research. We carried out several primary interviews with market experts from both the demand and supply sides. On the demand side, we interviewed professionals from the pharmaceutical and biopharmaceutical industries, as well as from contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). On the supply side, we spoke with C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.
The primary interviews were conducted across six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 65% of the interviews involved supply-side participants, while 35% were with demand-side participants. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were utilized to estimate and validate the overall size of the CRISPR market. These methods were also extensively employed to assess the sizes of various subsegments within the market. The research methodology for estimating the market size includes the following steps:
CRISPR Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a revolutionary tool used to edit genes in a way that resembles traditional GMO techniques. The use of the Cas9 enzymes differentiates CRISPR from other forms of genetic modification. CRISPR edits and rearranges genes by cutting out the damaged or unwanted part of the DNA, allowing the remaining DNA to be rearranged in a new way.
The report comprehensively analyzes the CRISPR market, covering a wide range of products & services such as CRISPR kits & enzymes, CRISPR libraries, gRNA synthesis, cell line development, and screening & validation.
Key Stakeholders
- Genome editing/genome engineering product manufacturers
- CRISPR editing/genome engineering product manufacturers
- Suppliers and distributors of genomic instruments/systems and consumables
- Contract manufacturing organizations
- Pharmaceutical and biotechnology companies
- Diagnostic centers and medical colleges
- Contract research organizations
- Government associations and research institutes
- Regulatory authorities
- Business research firms
Report Objectives
- To define, describe, and forecast the CRISPR market by offering, product, service, application, end user (products market), end user (services market), and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CRISPR market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Portfolio Assessment
- Product Matrix, which gives a detailed comparison of the product/service portfolios of the top three companies.
Company Information
- Detailed analysis and profiling of additional market players (up to three).
Geographical Analysis
- A further breakdown of the Rest of Asia Pacific CRISPR market into countries
- A further breakdown of the Rest of Europe CRISPR market into countries
- A further breakdown of the Rest of Latin America CRISPR market into countries
Get the Full CRISPR Market Report
Full forecast, segment splits, and company analysis for all CRISPR Market.
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report